- Enrolling by invitationPHASE2, PHASE3
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
This study is for cancer patients already taking the drug futibatinib in another study. It lets them continue treatment if it's helping and safe, ensuring ongoing care without interruption.
For: Advanced/Metastatic CancerUnited States · France · South Korea - RecruitingPHASE2
A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
This study looks at new ways to treat advanced cancers by matching specific drugs to changes found in a patient's tumour genes. It tests three different drugs – atezolizumab, futibatinib, and amivantamab – to see how well they shrink tumours in different groups of patients.
For: Advanced Solid TumorFrance · Germany · Italy - Active not recruitingPHASE2
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
This study is testing a new drug, futibatinib, alongside standard cancer treatments for people with advanced oesophageal or pancreatic cancer. We want to see if this new combination helps fight the cancer and how safe it is.
For: Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer · Esophageal Adenocarcinoma · Esophageal Squamous Cell CancerUnited States · France · Germany - RecruitingPHASE3
Personalized Medicine for Advanced Biliary Cancer Patients
This study looks at whether adding a special "targeted" drug after initial treatment for advanced bile duct cancer works better than continuing standard treatment. It customises treatment based on your tumour's unique features.
For: Biliary Tract NeoplasmsBelgium · France · United Kingdom - RecruitingPHASE1, PHASE2
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
This study is for children and young people with cancer that hasn't responded to usual treatments. It tests new medicines that target specific changes in cancer cells, aiming to find the right dose and see if they help. The goal is to find better ways to treat childhood cancer.
For: Pediatric CancerDenmark · France · Italy